West China Hospital Urology: Cancer, Reconstruction and Stone Teams

What kind of urology department is this

The official overview describes a clinical, teaching and research department with national clinical-key-specialty construction approval in 2012. Its subdivisions include urinary reconstruction, cancer MDT, stones, andrology, female urology, adrenal disease and robotic work. For an overseas enquiry, these distinctions provide a starting point for identifying the relevant clinical direction rather than assuming a general urology appointment covers every problem.

Its timeline traces urology teaching to 1915, records a southwest stone center in 2012 and a Sichuan kidney and urologic disease research center in 2023. The clinical divisions described below are more useful to a patient than the institutional chronology: a cancer review, a reconstruction question and recurrent stone disease involve different teams and different questions for assessment.

The cancer MDT and what it actually reviews

The hospital's urologic cancer multidisciplinary team was established in 2013 and covers prostate, kidney and urothelial cancers. Its stated participants come from urology, medical oncology, radiation oncology, pathology and imaging. Its clinical and research work links tumor-specific questions with input from these different disciplines.

The MDT's research includes intraductal prostate carcinoma, FH-deficient and TFE3-rearranged renal carcinoma, and urothelial organoids. Those examples distinguish the team's academic interests from a general cancer-service description. They are research directions, not a promise of access to an experimental treatment. A patient can ask how the existing diagnosis and any proposed plan would be reviewed, and which discipline would take responsibility for the next assessment.

The team's page names Wei Qiang as academic leader, describing him as leader of the urologic disease centre, discipline and institute. That is a statement about academic and disciplinary leadership on the checked page; it should not be read as confirmation of who currently holds an administrative department-head post. Zeng Hao is named as younger academic leader, not as director.

Reconstruction: urethral, ureteric and pelvic-floor problems

The urinary repair and reconstruction group lists Li Hong and Wang Kunjie as academic leaders. Its stated focus includes urethral stricture, urinary fistula, ureter reconstruction, female pelvic-floor problems and voiding dysfunction. These are problems where the decision is often about which reconstruction is appropriate, what tissue or material would be used, and what the patient's previous surgery and current function allow.

For an enquiry after previous urinary surgery, distinguish the original problem from what remains unresolved: a structural issue, ongoing symptoms or a proposed reconstruction needing another opinion. Ask the receiving team which existing operative information it would need and how it would explain the available alternatives. The academic leaders named on a program page are not a guarantee of personal appointment.

The group describes multidisciplinary research into structural problems, biomaterials and nerve recovery, and contributions to guideline work. Research activity of this kind indicates an academic interest in reconstruction; it does not establish that a particular technique is suitable for a particular patient, nor does it predict how anyone will recover.

Stones, including complex and staghorn cases

The stone programme names Li Hong and Wang Kunjie as academic leaders and Wang Jia as executive deputy of the stone centre. Its page documents work on complex and staghorn stones and describes percutaneous and flexible ureteroscopic approaches. It also records guideline and consensus contributions and training links with international endourology bodies.

The program records training links with SIU and endourology organizations. These describe educational activity rather than treatment accreditation or a personal outcome. Complex or staghorn stone work is a documented focus, but the page does not select a procedure for an individual. Ask the receiving team what it would need to assess the case and how it would explain the alternatives.

An enquiry after earlier stone treatment can state what was done, what diagnosis is currently recorded and which question remains unanswered. For example, is another opinion sought on a proposed procedure or on the next assessment? That distinction allows a response to address the unresolved decision rather than simply reproduce a list of techniques. Ask which existing reports should be supplied before sending a complete archive.

The robotic programme and its dated history

The robotic minimally invasive urology page gives a dated account: a robot was introduced in 2015, with Wei Qiang, Li Xiang and Zhu Yuchun named as early contributors. It describes robotic prostatectomy, cystectomy, kidney-preserving tumour surgery, adrenal surgery and ureter reconstruction. Wei Qiang is also associated on that page with an undated Gold Cystoscope recognition.

This is a dated development account: its numerical activity stops in April 2019. The names describe contributors to that program history, not a confirmed current operating team. The range of procedures explains why robotics appears within several urologic subdivisions rather than as a separate diagnosis. Ask how the relevant cancer, reconstruction or stone team would assess the underlying problem first.

Robotic assistance is a surgical approach, not a guarantee of suitability or of a better result. The relevant questions are clinical: whether a robotic approach is appropriate for this tumour or reconstruction, what the alternatives are, and what the treating team's own plan and risk discussion would cover. The hospital, not an enquiry service, makes that judgement.

Honours, awards and how to read them

The cancer MDT page associates Wei Qiang with the Wu Jieping Urology Medicine award and Tianfu Famous Doctor recognition, without years. The reconstruction page records Li Hong with a lifetime-contribution recognition from the World Chinese Urological Association, also undated, and Wang Kunjie with a 2022 Wu Jieping Urology Medicine award. The reconstruction team is recorded as receiving a 2021 Sichuan teaching-achievement First Prize.

The teaching recognition and the individual awards have different subjects. They help explain the department's education and academic activity, but do not identify which reconstruction or cancer approach an individual should receive. An enquiry should therefore connect the relevant disease direction with a clear question for assessment, rather than ask for treatment solely because an award recipient is associated with the department.

The department placed second in the Fudan 2023 national specialty reputation list. This historical reference concerns urology as a department, not a current ranking of its cancer, reconstruction or stone programs. It does not rank individual clinicians. For a patient comparing possible assessments, the more specific information is the clinical direction and the question that the proposed team would actually review.

Practical decisions before you send records

The first decision is which direction your question belongs to: a cancer review, a reconstruction problem, a stone problem, or something that crosses these. A short summary stating the diagnosis or suspected problem, the main question and what has already been done is enough to start. Detailed imaging and pathology can follow once the hospital's requirements are clear.

ChinaSpecialistCare can organise a urology enquiry, help prepare records and coordinate visit arrangements after the hospital accepts a case. We are an independent service, not the hospital, and cannot guarantee a named specialist or treatment outcome. A brief initial enquiry is free; an optional proxy consultation is not a prerequisite.

Urology care and surgery in China